Skip to main content

Table 2 Observed responses (mean) in 24 full factorial design for HVD-NLCs

From: Lyophilized Hybrid Nanostructured Lipid Carriers to Enhance the Cellular Uptake of Verapamil: Statistical Optimization and In Vitro Evaluation

Formula code Factors Responses
A B C D PS (nm) PDI ZP (mV) EE (%)
VER-1 20 270 15 200 207.33 ± 5.68 0.562 ± 0.019 − 37.5 ± 1.17 74.35 ± 4.00
VER-2 30 270 15 200 183.7 ± 5.38 0.629 ± 0.012 − 40.4 ± 1.31 61.01 ± 3.06
VER-3 20 285 15 200 204.5 ± 3.078 0.556 ± 0.049 − 43.8 ± 1.35 77.63 ± 9.36
VER-4 30 285 15 200 189.86 ± 3.76 0.546 ± 0.049 − 43.7 ± 1.31 83.15 ± 6.08
VER-5 20 270 30 200 203.06 ± 4.65 0.409 ± 0.052 − 45.9 ± 2.71 72.33 ± 9.64
VER-6 30 270 30 200 209.5 ± 3.47 0.327 ± 0.037 − 47.5 ± 2.45 72.08 ± 3.95
VER-7 20 285 30 200 201.46 ± 2.36 0.383 ± 0.029 − 49.1 ± 0.953 76.48 ± 17.81
VER-8 30 285 30 200 182.6 ± 6.95 0.382 ± 0.022 − 48.1 ± 1.36 67.11 ± 5.37
VER-9 20 270 15 300 188.4 ± 4.9 0.462 ± 0.043 − 49.1 ± 1.55 97.21 ± 1.615
VER-10 30 270 15 300 170.73 ± 5.53 0.526 ± 0.03 − 45.6 ± 1.17 91.71 ± 9.19
VER-11 20 285 15 300 190.3 ± 8.22 0.451 ± 0.033 − 46.7 ± 1.7 98.81 ± 1.012
VER-12 30 285 15 300 167.96 ± 1.76 0.589 ± 0.101 − 44.5 ± 3.5 84.56 ± 0.162
VER-13 20 270 30 300 173.46 ± 0.75 0.501 ± 0.019 − 46.7 ± 1.13 93.95 ± 4.10
VER-14 30 270 30 300 157.46 ± 3.61 0.429 ± 0.023 − 49.6 ± 2.39 79.86 ± 1.15
VER-15 20 285 30 300 178.36 ± 2.65 0.489 ± 0.048 − 48.1 ± 1.58 95.39 ± 2.16
VER-16 30 285 30 300 162.86 ± 3.35 0.436 ± 0.031 − 49.4 ± 1.08 77.88 ± 2.78
  1. A homogenization time (min), B solid lipid concentration (mg), C liquid lipid concentration (mg), D surfactant concentration (mg), PS particle size, PDI polydispersity index, ZP zeta potential, EE entrapment efficiency